Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thy1 single-chain variable fragment (Thy1-scFv)** is a recombinant antibody fragment that specifically targets the thymocyte differentiation antigen 1 (Thy1/CD90), a cell-surface glycoprotein overexpressed in the neovasculature of various cancers, notably pancreatic ductal adenocarcinoma (PDAC)[1]. This molecule is engineered as a single-chain variable fragment (scFv), combining the variable regions of the heavy and light chains of an antibody into a single polypeptide via a flexible linker. Thy1-scFv retains high binding specificity to Thy1, enabling its use in molecular imaging for early cancer diagnosis, particularly for PDAC, where over 80% of cases show Thy1 upregulation in tumor vasculature[1][2][4]. It is typically produced via recombinant expression in *E. coli*, and it can be conjugated to imaging agents, such as ultrasound contrast microbubbles, to enable targeted detection of tumors in vivo[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Thy1 single-chain variable fragment.